Published in Sci Transl Med on April 15, 2015
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science (2017) 2.69
The genomic landscape of response to EGFR blockade in colorectal cancer. Nature (2015) 1.39
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun (2015) 1.33
Next-generation sequencing to guide cancer therapy. Genome Med (2015) 1.31
Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. Gynecol Oncol (2015) 0.98
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget (2015) 0.98
Defining "mutation" and "polymorphism" in the era of personal genomics. BMC Med Genomics (2015) 0.97
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep (2015) 0.96
Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection. Cancers (Basel) (2015) 0.94
Ambient Ionization Mass Spectrometry for Cancer Diagnosis and Surgical Margin Evaluation. Clin Chem (2015) 0.93
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med (2016) 0.92
Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes. Brief Bioinform (2015) 0.91
Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories. J Natl Cancer Inst (2015) 0.90
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open (2016) 0.88
Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). BMC Genomics (2015) 0.85
Omics Profiling in Precision Oncology. Mol Cell Proteomics (2016) 0.85
Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med (2016) 0.84
Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight (2016) 0.82
Defining actionable mutations for oncology therapeutic development. Nat Rev Cancer (2016) 0.82
Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach. Mol Cell Proteomics (2015) 0.82
Integrative clinical genomics of metastatic cancer. Nature (2017) 0.82
Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings. Clin Cancer Res (2016) 0.82
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. Oncologist (2016) 0.80
Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces. PLoS One (2016) 0.80
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. J Immunother Cancer (2016) 0.79
Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing. World J Gastroenterol (2016) 0.79
The future of clinical cancer genomics. Semin Oncol (2016) 0.79
Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories. Int J Mol Sci (2016) 0.78
Digital Sorting of Pure Cell Populations Enables Unambiguous Genetic Analysis of Heterogeneous Formalin-Fixed Paraffin-Embedded Tumors by Next Generation Sequencing. Sci Rep (2016) 0.78
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle. Cold Spring Harb Mol Case Stud (2016) 0.78
Identification of a Novel Pathogenic Germline KDR Variant in Melanoma. Clin Cancer Res (2015) 0.78
Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. Oncologist (2017) 0.78
In vivo severity ranking of Ras pathway mutations associated with developmental disorders. Proc Natl Acad Sci U S A (2017) 0.77
The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response. Oncotarget (2016) 0.77
TMC-SNPdb: an Indian germline variant database derived from whole exome sequences. Database (Oxford) (2016) 0.77
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res (2016) 0.77
Genomic alterations in pancreatic cancer and their relevance to therapy. World J Gastrointest Oncol (2015) 0.77
Genomic sequencing of only tumor tissue could be misleading in nearly half of patients, study shows. BMJ (2015) 0.77
AACR Project GENIE: Powering Precision Medicine Through An International Consortium. Cancer Discov (2017) 0.77
Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools. Oncotarget (2016) 0.76
Integrating cancer genomic data into electronic health records. Genome Med (2016) 0.76
Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. Clin Cancer Res (2016) 0.76
Ethical qualms about genetic prognosis. CMAJ (2016) 0.75
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution. PLoS One (2016) 0.75
Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models. Nucleic Acids Res (2016) 0.75
Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. Sci Rep (2016) 0.75
Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer. World J Gastroenterol (2016) 0.75
Rational design of cancer gene panels with OncoPaD. Genome Med (2016) 0.75
Comparison of genetic variants in matched samples using thesaurus annotation. Bioinformatics (2015) 0.75
Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing. BMC Med Genomics (2016) 0.75
Comparison of the seleno-transcriptome expression between human non-cancerous mammary epithelial cells and two human breast cancer cell lines. Oncol Lett (2017) 0.75
TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Oncotarget (2016) 0.75
Genomic mutation-driven metastatic breast cancer therapy: a single center experience. Oncotarget (2017) 0.75
Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine. Oncotarget (2016) 0.75
Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4. J Pathol (2017) 0.75
Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. Genet Med (2017) 0.75
An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course. Cold Spring Harb Mol Case Stud (2017) 0.75
Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma. Rare Tumors (2017) 0.75
A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol (1970) 155.96
A map of human genome variation from population-scale sequencing. Nature (2010) 121.13
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Predicting deleterious amino acid substitutions. Genome Res (2001) 28.95
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
CDD: a Conserved Domain Database for the functional annotation of proteins. Nucleic Acids Res (2010) 19.07
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res (2013) 9.31
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
LOVD v.2.0: the next generation in gene variant databases. Hum Mutat (2011) 5.53
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet (2013) 3.27
Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov (2012) 3.25
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med (2014) 3.18
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet (2013) 2.83
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov (2014) 2.64
Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat (1996) 2.54
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics (2011) 2.24
A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer (2010) 1.91
Genetic landscape of esophageal squamous cell carcinoma. Nat Genet (2014) 1.89
Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther (2010) 1.77
Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am J Clin Pathol (2014) 1.21
Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-T patients. Am J Med Genet (2000) 1.21
RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. J Clin Pathol (2014) 1.07
Comprehensive screening for mutations associated with colorectal cancer in unselected cases reveals penetrant and nonpenetrant mutations. Int J Cancer (2014) 0.93
Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. Breast Cancer Res Treat (2011) 0.89
Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med (2017) 0.84
Circulating tumor DNA moves further into the spotlight. Genome Med (2014) 0.83